In the past six months, several major multinational corporations have invested heavily in acquiring radiopharmaceutical companies, including Eli Lilly's acquisition of POINT Biopharma, Bristol-Myers Squibb's purchase of RayzeBio, and AstraZeneca's partnership with Fusion Pharmaceuticals. These significant deals have sparked a global wave of investment in the radiopharmaceutical sector, also known as nuclear medicine.

Glotope, a China-based CRO/CDMO platform with a global perspective, will be hosting the "Nuclear Medicine Development Lecture Hall" on April 18-19.We will present the "Comprehensive Radiopharmaceuticals Development Workshop," unveiling high-potential targets in nuclear medicine R&D, sharing updates on the radiopharmaceutical industry and regulations, and decoding lifecycle strategies for radiopharmaceutical development. Our goal is to provide professional solutions to common challenges in the nuclear medicine industry and accelerate the advancement of high-potential projects. 

From April 18 to 19, leading companies and over a hundred experts from across the globe will gather at Chengdu Medical City. Guests from various fields, including government, industry, academia, research, finance, and media, will join us for the "Inaugural XDC New Drug Conference." In addition to the "Comprehensive Nuclear Medicine Development Workshop" on the morning of April 18, we will host engaging sessions on the afternoons of April 18 and 19, including "New Models and Case Analysis of Innovative Nuclear Drug R&D and Commercialization" and "An Overview of Domestic and International Radiopharmaceutical Production Regulations."    

We invite you to visit Glotope's booth A30 to explore cutting-edge knowledge in the nuclear medicine field and share insights. We look forward to engaging with you and driving the future of the pharmaceutical industry together!

Glotope Conference Information

Whole process development of nuclear medicine (workshop)

April 18 09:00-12:00

09:00-09:30 New targets lead the future, sharing the latest developments in radiopharmaceuticals

Shen Di: Head of Guotong New Drug Innovation Promotion

09:30-10:00 Comprehensive analysis of radiopharmaceutical CMC

Xu Jianfeng: Director of CMC of Guotong New Drugs

10:00-10:30 Analysis of non-clinical evaluation strategies for RDC new drugs

Fu Peng: Biopharmaceutical industry review expert at Shenzhen Development and Reform Commission/Assistant President of Beijing Safe Pharmaceutical Research Institute

10:30-11:00 Tea break

11:00-11:30 Strategies and Practices: The Road to Radiopharmaceutical Registration

Liu Shuang: Senior Vice President of Xiantong Pharmaceutical

11:30-12:00 Looking at the radiopharmaceutical track from an investment perspective

Geng Xueli: Executive General Manager of SDIC Venture Capital

Future Nuclear Medicine Conference - Session 1: Embracing the Future of Nuclear Medicine Industry

April 18

16:20-16:40 From importing to exporting: New models and case analysis of innovative nuclear medicine R&D and commercialization

Bai Ge: Vice President of Xiantong Pharmaceutical

Future Nuclear Medicine Conference - Session 3: Nuclear Medicine Upstream and Downstream Industry Chain Forum

April 19

14:00-14:20 Discussion on the differences in domestic and foreign radiopharmaceutical production supervision regulations

Wang Song: Vice President of Quality of Guotong New Drugs

 
XDC New Drug Conference Information

XDC New Drug Conference Time | April 18-19, 2024

XDC New Drug Conference Venue | Crowne Plaza Wenjiang, Chengdu

XDC New Drug Conference Scale | 1,000+ people